Caroline Seymour joined MJH Life Sciences in 2018 and has expertise in video production and print/digital publication. Email: cseymour@onclive.com
Novel Drug Appears Safe and Active for Advanced Solid Tumors
June 3rd 2020The CD71-directed probody-drug conjugate (PDC) of monomethyl auristatin E (MMAE) CX-2029 showed tolerability and antitumor activity in patients with advanced cancer, according to findings from the first-in-human phase 1/2 PROCLAIM-CX-2029 trial (NCT03543813) that were presented during the 2020 ASCO Virtual Scientific Program.
Expert Discusses Exciting Advancements in Sarcoma Treatment
April 30th 2020Though the use of next-generation sequencing (NGS) may not have immediate clinical implications for patients with sarcoma, it can provide valuable information for data collection and position patients for ongoing clinical trials that have the potential to push the needle forward, explained Gina Z. D'Amato, MD.
Anticoagulation Is Key for Adjunctive Therapy in Thrombosis Management
April 18th 2020Patients at risk of developing thrombosis should receive anticoagulants, in the form of Xa inhibitors and, if necessary, andexanet alfa (Andexxa) or prothrombin concentrates to control excessive bleeding, explained Alvin H. Schmaier, MD.
PARP Inhibitors Continue to Show Promise in Prostate Cancer Treatment
March 31st 2020The use of PARP inhibitors against DNA damage repair (DDR) alterations in prostate cancer is the first display of the potential for widespread precision medicine in the field, according to William K. Oh, MD, in a presentation during the 13th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.
Insufficient Data on Cancer Care During the COVID-19 Pandemic
March 26th 2020In the absence of definitive data regarding the risk of COVID-19 to patients with cancer and information to guide daily treatment decisions in the interim, Petros Grivas, MD, recommended converting the majority of patient visits to telehealth appointments and basing a patient’s need for treatment on their medical comorbidities, performance status, and cancer risk.
Individualized Treatment Is Key for mCRC
March 5th 2020Key elements that should inform treatment decisions for patients with metastatic colorectal cancer (mCRC) include molecular profiling, tumor sidedness, and microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) status, according to Michael J. Overman, MD.
Personalized Treatments, HER2-Directed Drugs Are Changing the Breast Cancer Space
February 23rd 2020The fields of early-stage hormone receptor (HR)–positive and metastatic HER2-positive breast cancer have made great strides in recent years, said Neelima Denduluri, MD, and such progress could be attributed to the emergence of tailored treatment strategies and the use of HER2-directed agents, respectively.
Next-Generation Imaging Will Change Prostate Cancer Paradigm
January 11th 2020Novel next-generation imaging modalities have greater visibility than conventional imaging tools, leading to higher detection rates and earlier treatment of early recurrences and metastatic disease among men with prostate cancer, explained Hussein Aoun, MD.
Overcoming AI Resistance in ESR1-Mutant Breast Cancer
December 7th 2019Resistance to aromatase inhibitors (AIs) is a growing concern in patients with advanced hormone receptor (HR)–positive, HER2-negative breast cancer, said Hope S. Rugo, MD, FASCO, who added that although fulvestrant (Faslodex) has shown some activity in patients who develop ESR1 mutations, more effective treatment options are needed.
Establishing Medical Fitness is the First Step in Treating Patients with Advanced Ovarian Cancer
August 26th 2019Before considering intraperitoneal chemotherapy, or dose-dense chemotherapy, for newly diagnosed patients with advanced ovarian cancer, it's not vital to first determine whether the patient is medically fit for these treatments.
The Treatment Landscape for Recurrent Ovarian Cancer Is Evolving
August 25th 2019Chemotherapy is the foundation of treatment for patients with recurrent ovarian cancer, but according to Madeleine B. Courtney Brooks, MD, MPH, conversations regarding the potential for secondary debulking and use of bevacizumab (Avastin) may also be warranted.
Expert Talks Major Advances in the Blood Cancer Space
July 8th 2019Now that the CD19-targeted CAR T-cell therapies axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah) have shown durable responses in the relapsed/refractory settings of non-Hodgkin lymphoma, researchers are hopeful that earlier exposure may heighten the curative potential of the modality, explained Mazyar Shadman, MD, MPH.
New Therapies Are Coming for Lung Cancer With Rare Mutations
May 28th 2019In non–small cell lung cancer (NSCLC), KRAS G12 mutations have been historically difficult to target, and research efforts dedicated to the development of effective targeted therapies for NRG1 fusions have not been successful. However, several biopharmaceutical companies are in the early stages of addressing that challenge, explained Sai-Hong I. Ou, MD, PhD.